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1. Introduction 
Squamous carcinoma of the oral cavity is a slow multi-steps process, based on progressive 
accumulation of genetic events leading to the selection of clonal populations of transformed 
epithelial cells (Ha&Califano, 2002) The spectrum of histological changes occurring in this 
process ranges from atypical squamous hyperplasia to carcinoma in situ (CIS), and is 
grouped under the designation of oral intraepithelial lesions (OILs) (Gale et al, 2005; Gale et 
al 2006). In their evolution, most cases of OILs are self-limiting and reversible, whereas some 
persist and may progress to SCC in spite of careful follow-up and treatment (Kambicˇ&Gale, 
1986; Crissman et al, 1993). 
As for the largest group of head and neck intraepithelial lesions, in the last years, various 
aspects of oral carcinogenesis have been investigated, including the aetiology, histological 
classification, treatment, frequency of malignant transformation and predictive factors. 
Particular attention has been directed to the analysis of the interrelationship between 
histological parameters and their biological behaviour (Gale et al 2005, Gale et al 2006; 
Kambicˇ&Gale, 1986; Putney&O’Keefe 1953; Kambicˇ 1978; Crissman 1979; Henry 1979; 
Hellquist et al, 1982; Gillis et al, 1983; Grundmann 1983; Goodman 1984; Crissman&Fu 1986; 
Velasco et al 1987; Olde-Kalter et al 1987; Crissman&Zarbo 1989; Sllamniku et al 1989; 
Bouquot et al, 1991a; Kambic&Gale 1995; Hellquist et al 1999; Gale et al, 2000; Gallo et al 
2001; Ricci et al 2003). These analyses have been recently further supplemented by molecular 
genetic investigations trying to include the molecular events involved in the pathogenesis of 
oral squamous cell carcinoma (OSCC) to improve the prognostic evaluation of OIN 
(Ha&Califano 2002; Somers et al 1992; Saglam et al 2007). 
A precise and uniform terminology of squamous intraepithelia lesions is essential for 
successful collaboration among pathologists, as well as for proper communication with 
clinicians. The terminology used in clinical and pathological reports has changed 
significantly over the last six decades. Common agreement has recently been achieved for 
terms that are used only for the clinical appearance and do not have any histopathological 
and prognostic implications. The most frequently applied clinical diagnoses are oral 
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leukoplakia and erythroplakia (Kambicˇ&Gale 1995; Gale et al 2000; Gallo et al 2001). In 
contrast, keratosis remains a controversial term, since it is often wrongly applied 
interchangeably to macroscopic and microscopic features, whereas it really represents a 
histological term denoting the appearance of a keratin layer on the surface of the squamous 
epithelium. 
Unfortunately, inconsistent terminology still exists for the histological classification of OIN. 
The spectrum of epithelial changes has been variously described as keratosis, dysplasia, 
squamous intraepithelial neoplasia (SIN), oral intraepithelial neoplasia (OIN), etc, to list 
only the most commonly used terms. Because of our inability to harmonize different views 
and establish a single classification of squamous intraepithelial lesions, there are three 
classification schemes in the most recent edition of the World Health Organization (WHO) 
classification of tumours, pathology of the head and neck tumours, as follows: (i) dysplasia 
system, (ii) SIN system, and (iii) Ljubljana classification (Gale et al 2005). These 
classifications differ conceptually and terminologically, and analogy between them can only 
be approximate.  
Chronic inflammation, leukoplakia or, occasionally, erythroplakia, appear mainly in the 
buccal mucosa, labial commissure, gingiva/alveolar ridge, tongue, floor of the mouth. 
Lesions can be either sharply circumscribed and grow exophytically, or be predominantly 
flat and diffuse, related in part to the amount of keratin layer. Their surface is rough, may be 
muddy brown to red (erythroplakia), perhaps with increasingly visible vascularity, or 
coated with diffuse or dispersed circumscribed whitish plaques. A circumscribed whitish 
thickening of the mucosa may be observed, covered by irregularly exophytic warty plaques. 
A speckled appearance of lesions can also be present, caused by an unequal thickness of the 
keratin layer (Gale et al 2005; Kambic&Gale 1995). Some leukoplakic lesions are ulcerated 
(6.5%) or combined with erythroplakia (15%) (Bouquot et al 1991a). In general, leukoplakic 
lesions are thought to have a low risk of malignant transformation, mixed white and red 
lesions, or speckled leukoplakia, an intermediate risk, and pure erythroplakia (red lesions) 
the highest risk of cancer development. However, none of these features can be used as an 
indicator of the overlying changes of the epithelium, and histological analysis of these 
lesions is mandatory to determine their biological potential. 
Symptoms depend on the location and severity of the disease and usually last a few months 
before clinical notice. 
2. Clinical classification of leukoplakia and epithelial dysplasia 
Leukoplakia, erythroplakia and palatal keratosis, associated with reverse smoking, are 
categorized as precancerous lesions (Axell et al 1996; Pindborg JJ et al 1997). Oral 
leukoplakia is the most common disease among precancerous lesions, whereas 
erythroplakia is relatively uncommon, and palatal keratosis associated with reverse 
smoking is rarely reported in Japan (Warnakulasuriya et al 2007). Pindborg et al (1963) 
confirmed that speckled leukoplakia, which is characterized by the presence of white 
nodular patches or white lesions interspersed with erythematous areas, was often associated 
with epithelial dysplasia or carcinoma. These findings were supported by subsequent 
reports showing the association of nonhomogeneous leukoplakia with epithelial dysplasia 
(Silverman et al 1976; Gupta et al 1980). The two-tiered clinical classification system, used to 
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divide oral leukoplakia into homogeneous and nonhomogeneous leukoplakia, was created 
by an international symposium (Axell et al 1996; Pindborg et al 1997). Under this system, 
homogeneous leukoplakia is further divided into four subtypes: flat, corrugated, wrinkled, 
or pumice; and similarly nonhomogeneous leukoplakia is subdivided into four types: 
verrucous, nodular (speckled), ulcerated, or erythroleukoplakia. The adjective 
‘‘nonhomogeneous’’ refers to the color (i.e., a mixture of white and red changes for 
erythroleukoplakia) and texture (i.e., exophytic, papillary, or verrucous) of the lesion (van 
der Waal et al 1997). However, with regard to nonhomologous lesions, there are no 
reproducible criteria under this system for the clinical differentiation of proliferative 
verrucous leukoplakia from verrucous hyperplasia or verrucous carcinoma (van der Waal et 
al 1997; Shear&Pindborg 1980). 
Sugar& Banoczy (1969) reported that leukoplakia erosiva and leukoplakia verrucosa were 
more often associated with epithelial dysplasia than leukoplakia simplex. Furthermore, 
because the clinical features of oral leukoplakia in Japan did not correlate with the two 
aforementioned systems, Amagasa et al (1977) developed a clinical classification system of 
oral leukoplakia in Japan, which was subsequently further developed in 2006 (Amagasa et al 
2006). Under this system, oral leukoplakia is classified into four clinical types: type I, a flat 
white patch or plaque without red components; type II, a flat white patch or plaque with red 
components; type III, a slightly raised or elevated white plaque; and type IV, a markedly 
raised or elevated white plaque. Using this classification system, it was found that type II 
leukoplakia was significantly associated with epithelial dysplasia. 
3. Histopathological features of Squamous Intraepithelial Lesions (SILs) 
Traditional light microscopic examination, in spite of a certain subjectivity in interpretation, 
remains the most reliable method for determining an accurate diagnosis of SILs. Jackson 
first defined chronic laryngitis and keratosis as precancerous lesions (Jackson C, 1923); later, 
numerous studies and classifications have attempted to correlate phenotypic and genetic 
changes with the biological behaviour of the lesions (Michaels&Hellquist 2001). Regrettably, 
neither generally accepted criteria nor unified terminology have to date been provided for a 
histological grading system of oral SILs. Evidence of the inability of pathologists to set up a 
single, unified classification of SILs was manifest in the WHO Classification of head and 
neck tumours, published in 2005, where the dysplasia system is presented as the 2005 WHO 
classification simultaneously with the classification of SIN and the Ljubljana classification 
(Gale et al 2005). The majority of current classifications, such as the traditional dysplasia 
system (Hellquist et al 1982; Blackwell et al 1995), keratosis without (KWA) and with atypia ⁄ 
in situ carcinoma (CIS) (Crissman 1979; Crissman 1982), Squamous Intraepithelial Neoplasia 
(SIN) (Crissman et al 1993; Crissman&Zarbo 1989) and Laryngeal Intraepithelial Neoplasia 
(LIN), (Friedmann&Ferlito 1993; Resta et al 1992) follow criteria similar to those commonly 
used for epithelial lesions of the uterine cervix. However, the different aetiology of oral 
lesions and their particular clinical and histological features require a grading system more 
appropriate to this region (Hellquist et al 1999). One can object that grading SILs, in spite of 
the clear histological criteria, is an attempt to impose arbitrary distinct categories of a 
continually progressing process without naturally and sharply defined borders (Bosman 
2001; Kujan et al 2011). However, this continuous process, which is of long duration, may 
eventually stop, regress or progress, depending above all on the influence of various detri- 
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mental factors causing genetic and, consequently, phenotypic epithelial changes. When a 
biopsy is performed with a representative tissue sample, the established histological 
changes still serve at present as the main guidance for clinicians on how to treat the patient, 
as well as being the most reliable prognostic factor of the biological behaviour of the disease.  
4. A lesson from premalignant lesions of the uterine cervix 
One of the most significant advances in oncology has been the realization that cervical 
carcinoma arises from precursor lesions. There is probably more known about cervical 
neoplasia and its natural history than about any other human epithelial neoplasm. Most 
medical authorities now agree that cervical cancer is the end stage of a continuum of 
progressively more atypical changes in which one stage merges imperceptibility with the 
next. The first and apparently earliest change is the appearance of atypical cells in the basal 
layers of the squamous epithelium, but this occurs alongside normal differentiation toward 
the prickle and keratinizing cell layers. As the lesion evolves, there is progressive 
involvement of more and more layers of the epithelium, until it is totally replaced by 
atypical cells, exhibiting no surface differentiation (Robbins&Cortran 1979). 
The most widely used term for the various stages in the evolution of these precursor lesions 
is ‘‘dysplasia’’ (Reagan&Hamonic 1956), which literally means bad molding or, in more 
scientific terms, disordered development. In WHO’s 1975 ‘‘Histological Typing of Female 
Genital Tract Tumours’’ (Poulsen et al 1975), dysplasia is subdivided into mild, moderate 
and severe, depending on the thickness of the squamous epithelium involved by atypical 
cells. When there is full-thickness involvement, we use the term ‘‘carcinoma in situ’’, which 
was coined by Broders in 1932 in relation to head and neck lesions (Bouquot et al 2006; 
Broders 1932).  
A newer terminology, ‘‘cervical intraepithelial neoplasia’’ (CIN), was subsequently 
proposed in an attempt to emphasize that these dysplastic changes represent a spectrum of 
the same basic changes (Richart 1966; 1973). CIN involves one or more clones of transformed 
cells slowly replacing normal keratinocytes, starting from the basal and parabasal layers to 
progressively invading the entire epithelial height. Richart subdivided CIN into three 
grades, CIN I, CIN II and CIN III, corresponding to mild, moderate and severe dysplasia, 
respectively, which then progresses to CIS. 
The classifications and concepts of premalignant lesions of the uterine cervix have been 
extended to all other mucosal sites covered by squamous epithelial as oral mucosa. 
5. WHO classification 
In 1973, WHO defined an oral premalignant lesion as ‘‘a morphologically altered tissue in 
which oral cancer was more likely to occur than in its apparently normal counterpart’’; more 
recently, researchers have recommended use of the term ‘‘potentially malignant disorder’’ 
(Warnakulasuriya et al 2007). Under the WHO classification, atypical epithelium is divided 
into two pathological entities, one with progression to SCC and the other without 
progression. Although the former is a true premalignant lesion and the latter is a reactive 
atypical epithelium, the concept of epithelial dysplasia (mild, moderate or severe) includes 
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both lesions and is a borderline category which can be placed in neither of the WHO’s 
classifications. 
As mentioned earlier, the dysplasia–carcinoma sequence theory as applied to the oral 
mucosa was adopted from the case of the uterine cervix, and the fundamental view of the 
WHO classification for oral cancer remained unchanged for more than three decades, from 
the first edition in 1971 (Wahi et al 1971, Napier&Speight 2008) to the latest version in 2005 
(Gale et al 2005). WHO’s ‘‘Histo-pathological Typing of Cancer and Precancer of the Oral 
Mucosa’’ (Pindborg et al 1997), is now used as a worldwide standard guide to diagnosis. 
The dysplastic features of oral mucosa are characterized by cellular atypia and loss of 
normal maturation and stratification, and the more severe the dysplasia, the greater the 
likelihood of malignant transformation. On the basis of the various criteria thought to be 
typical for the transformation of a dysplastic lesion to carcinoma, lesions are most frequently 
graded into one of four different groups: mild, moderate or severe dysplasia, or CIS, with 
the latter considered to be pre-invasive malignancy at the extreme end of epithelial 
dysplasia. Several histopathological changes may occur in epithelial dysplasia (Pindborg 
1980). The criteria used for diagnosing dysplasia are provided in the form of a table in the 
WHO classification of tumours for the head and neck. Within the frame-work of the grading 
system of dysplasia, the more prominent or more numerous these factors are, the more 
severe the grade. These factors are limited to the lower third of the epithelium in mild 
dysplasia and extend to lower two-thirds of the epithelium in moderate dysplasia upward 
to the outer layer (Gale et al 2005). The use of the terms full thickness or almost full 
thickness architectural abnormalities is also recommended for the diagnosis of CIS. 
This grading system of one-third, two-thirds and full thickness was described for the first 
time in the latest version of WHO’s classification of head and neck tumours although it had 
been clearly referred to in the classification of uterine cervix since 1975 (Poulsen et al 1975). 
The large number of factors in this grading system would appear to be the basis of the many 
problems associated with the subjectivity of diagnosis (Pindborg 1980; Karabulut et al 1995; 
Holmstrup et al 2006). Accordingly, examination of the universality (inter-observer 
variability) and reproducibility (intra-observer variability) of this grading system for 
diagnosis has been carried out in recent years (Warnakulasuriya et al 2007; Kujan et al 2006; 
Kujan et al 2007; Ficher et al 2004; Tabor et al 2003; Abbey et al 1995; Brothwell et al 2003; 
Speight et al 1996) to sharply discriminate “indolent” low grade lesions, potentially 
reversible, from throughly preneoplastic high grade lesions. To this end, a novel binary 
grading system (low risk and high risk) designed to simplify the WHO classification and to 
raise the reproducibility of diagnosis has been advocated (Jares et al 1994; Califano et al 
1996). 
The histopathological criteria of dysplasia in the WHO classification are widely accepted 
among pathologists, and the concept of epithelial dysplasia outlined in the classification is 
considered to be correct in many cases (Crissman et al 1993; Putney&O’Keefe 1953; Ricci et 
al 2003; Franchi et al 2001). The notion that atypical cells progress from the basal layer to the 
surface is widely accepted in terms of the universality and reproducibility of diagnosis. 
However, it has become clear that there is a fatal flaw in this grading system as it does not, 
in practice, accurately reflect the clinical behaviour (Crissman&Zarbo 1989; Voravud et al 
1993; Nadal&Cardesa 2003; Sanz-Ortega et al 2003; Chatrath et al 2003). The grades do not 
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offer clear therapeutic guidelines to clinicians for appropriate management. For CIS at least, 
the WHO grading system diagnoses CIS showing maturation and differentiation as lower 
risk lesions, and these lesions account for a large proportion of cases in the oral mucosa 
(Hellquist et al 1982; Gillis et al 1983; Yoo et al 2004; Kleist&Poetsh 2004; Jeannon et al 2004; 
Chi et al 2004). 
6. SIN/dysplasia classification 
In response to the concept of CIN in the uterine cervix, a similar view developed for the oral 
mucosa. In 2002, Kuffer&Lombardi stated that malignant transformation is a multistep 
process that should be approached from the histological—not merely clinical—standpoint. 
Intraepithelial neoplasia, a concept created in relation to the uterine cervix and already 
extended to other mucosae, should also be adapted for the case of the oral mucosa and used 
as diagnostic term: the use of the term oral intraepithelial neoplasia represents not only a 
change in terminology, but also progress in unifying the concept of the precursors of 
squamous cell carcinoma, while at the same time suppressing the futile debate about severe 
dysplasia and CIS. Furthermore, grading lesions as low- and high-grade OIN increases 
diagnostic consistency. 
SIN/dysplasia in the oral cavity has been found to take two distinct morphological forms, at 
opposite ends of the SIN/ dysplasia spectrum: hyperplastic keratinizing SIN/dysplasia and 
atrophic SIN/dysplasia, which are clinically compatible with leukoplakia and erythroplakia, 
respectively. The former is keratinizing dysplasia and the latter is the classic (WHO type) 
form of dysplasia. As a complication, the features of these extremes overlap. Caution must 
be exercised as the admixture type of these two ends of the spectrum is commonly 
underdiagnosed and may not be recognized as high-grade SIN/dysplasia. 
The SIN/dysplasia classification, a modification of the WHO grading system, proposes a 
category of keratinizing dysplasia to designate lesions showing superficial keratinization in 
association with high-grade cytological atypia in the lower epithelium (Crissman et al 1988; 
Blackwell et al 1995; Kambicˇ et al 1992; Kambicˇ 1997; Hellquist et al 1999; Crissman 1982). 
The authors suggesting this modification reported that these lesions have a high incidence 
of local relapse and a high progression rate to invasive SCC and, as such, they are included 
in the high-grade group as high-grade keratinizing SIN (Crissman&Sakr 2001; Sakr et al 
2009). The authors further stressed that abnormal differentiation is present in these lesions 
in the form of aberrant keratinization (dyskeratosis), manifesting as single-cell keratinization 
and keratin pearls, occurring in the midst of the epithelium. The histopathological features 
used for grading OIN according to WHO are listed below: 
1. Loss of polarity of the basal cells  
2. Proliferation of the basal cells  
3. Increased nucleus-to-cytoplasm ratio 
4. Epithelial hyperplasia with drop-shaped submucosal rete extension 
5. Irregular epithelial stratification and cellular pleomorphism 
6. Premature keratinization of single cells (dyskeratosis) or keratin pearls in the rete pegs 
7. Increased mitotic figures and abnormally superficial mitoses 
8. Presence of abnormal mitotic figures  
9. Variation in nucleus size, shape, and hyperchromatism; increased nucleus size  
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10. Increased number and size of nucleoli  
11. Abnormal variation in cell shape and size. 
The transition from normal epithelium to atypical epithelium and SCC is related to the 
progressive accumulation of genetic changes leading to a clonal population of transformed 
epithelial cells. Despite extensive research into these genetic changes in oral carcinogenesis, 
reliable genetic markers with diagnostic and prognostic value are still lacking (Gale et al 
2009). 
7. Ljubljana classification and SIL classification 
The Ljubljana classification was devised by laryngeal pathologists Kambic and Lenart in 
1971 (Hellquist et al 1999; Gale et al 2009; Kambic&Lenart 1971, Gale et al 2000). Based on 
clinical and histological observations, these authors adapted the classification to the specific 
demands of the oral cavity. The Ljubljana system nominally recognizes four grades: simple 
hyperplasia and basal/parabasal cell hyperplasia include mainly benign categories with a 
minimum risk of malignant alteration; atypical hyperplasia is potentially a malignant lesion; 
CIS is actually a malignant lesion (Kambic 1997; Gale et al 2000; Michaels 1997; Eversole 
2009; Fleskens&Slootweg 2009; Koren et al, 2002). The main features that differentiate the 
Ljubljana grading system from other classifications are the distinction between mainly 
benign (squamous hyperplasia and basal-parabasal hyperplasia) and potentially malignant 
(atypical hyperplasia) lesions, and the positive separation of CIS from atypical hyperplasia. 
These two entities differ in morphology and progression to invasive carcinoma. In this 
classification, all histopathological change is included until it results in SCC (Crissman et al 
1988; Sllamniku et al 1988; Crissman 1982). Although many studies have focused on the 
usefulness of this classification in relation to the larynx (Blackwell et al, 1995; Michaels 1997; 
Gale et al 2000; Kambic 1997; Frangez I et al, 1997), there is currently almost no verification 
of this in the oral mucosa (Mahajan&Hazarey 2004; Zerdoner 2003) so its usefulness cannot 
be discussed as yet. 
 
Fig. 1. Progression of Oral Cancer 
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The binary system which unites the SIN classification and the Ljubljana classification is 
advocated mainly by laryngeal pathologists. This system encompasses the Ljubljana 
classification into the SIN classification, with the concept of SILs being fundamentally the 
same (Gale et al 2009). The whole spectrum of histological changes, both reversible and 
irreversible, has recently been cumulatively designated as SIL, ranging from squamous 
hyperplasia to CIS. In terms of their evolution, some cases of SIL are self-limiting and 
reversible, some persist, and some progress to SCC despite careful follow-up and treatment. 
Although it would appear that both classifications can be unified, verification in the case of 
the oral mucosa remains to be determined. 
8. Mechanisms of developing OIN 
The genetic changes and the sequence of genetic events underlying the progression of 
normal mucosa to oral neoplastic tissue are still not entirely recognized. Between six and ten 
independent genetic events within a single cell have been estimated to be necessary for SCC 
development in the head and neck region. They are believed to be morphologically 
expressed as different grades of epithelial abnormality. The latency period between 
carcinogen exposure and appearance of malignancy may last up to 25 years. 
The process of tumorigenesis of solid tumours, including oral neoplasia, involves both 
activation of proto-oncogene products that stimulate growth, and inactivation of tumour-
suppressor genes (TSGs), the products of which normally inhibit cell proliferation (Califano 
et al 1996; Field 1996; Gallo et al 1997; Califano et al 2000). The identification and 
characterization of the comprehensive spectrum of genetic aberrations in SCC development 
may not only elucidate the process of carcinogenesis, but also provide promising diagnostic 
tools for early detection, prevention and assessment of cancer risk from precursor lesions. 
9. Genetic progression model 
Califano and co-workers have made two studies of cytogenetic alterations in head and neck 
carcinogenesis, which showed an increasing number of chromosomal alterations with the 
progression of Oral Intraepithelial Neoplasia (OILs), ranging from hyperplasia to CIS and 
invasive SCC. The areas of allelic loss, and less frequently allelic gain, are decisive elements 
in the progression model involving HNSCC. The results of Califano’s studies have revealed 
that the spectrum of chromosomal loss progressively increases at each histopathological 
step of squamous intraepithelial lesions from benign hyperplasia to CIS and invasive SCC. 
The earliest alterations appear on chromosomes 9p21, where the p16 gene resides, at 3p with 
at least three putative tumour-supressor loci, and at 17p13 where the p53 gene is located. 
Loss of chromosome region 9p21-22 appeared to be the most common of all genetic changes 
in HNSCC, with a frequency of 70% (van der Riet P et al 1994). Additional studies of 
microsatellite DNA allelic imbalance in oral carcinogenesis have confirmed that dysplasia 
correlates with loss of heterozygosity (LOH) at 3p21, 5q21, 9p21 and 17q13 (Sanz-Ortega J, 
2003). Yoo et al. have suggested that 9p21 is the earliest event, already appearing in 
squamous metaplasia, as well as in invasive and metastatic SCC. LOH at 17p13, 3p35 and 
3p14 was observed as an intermediate event, occurring from dysplasia to metastatic SCC 
(Yoo et al 2004). Micro-satellite instability (MSI), a novel marker of genetic instability, was 
also applied in a study to assess the risk of malignant progression in laryngeal preinvasive 
www.intechopen.com
 Novel Markers for Diagnosis and Prognosis of Oral Intraepithelial Neoplasia 
 
11 
lesions. The authors concluded that MSI is more common in preneoplastic oral lesions that 
have progressed to invasive SCC. They suggest that MSI assessment may be useful in 
determining the risk of malignant alteration in patients for whom chemopreventive and 
multiple endoscopic protocols can be attempted (Sardi et al 2006). 
 
Fig. 2. Genetic Progression Model 
10. Key tumour-suppressor genes in oral carcinogenesis 
Gene p16 can be inactivated by a variety of mechanisms, such as mutation, homozygous 
deletion and promoter hypermethylation (Kamb et al 1994; Merlo et al 1995). The p16 gene 
functions as an inhibitor of cyclin-dependent kinase 4 and 6, with subsequent abrogation of 
retinoblastoma (Rb) phosphorylation and G1 cell cycle arrest (Serrano et al 1993; Kim et al 
2004). Loss of chromosome region 9p21-22 occurs prior to the development of histological 
atypia, already at the level of hyperplastic mucosa, and is regarded as an early event in the 
development of HNSCC (Hasina&Lingen 2004). 
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Another important region identified by allelic loss is chromosome 17p, the site of the p53 
gene. It is involved in several key cell functions such as gene transcription, DNA synthesis 
and repair, cell-cycle coordination and apoptosis. Mutation ⁄ inactivation of the p53 gene has 
been detected in approximately 50%, but may be present in as high as 80% of HNSCCs (Balz 
et al 2003). It remains unclear whether p53 gene inactivation is an early or late event of oral 
carcinogenesis. According to Boyle and co-workers, it occurs in the transition from the 
preinvasive to invasive form (Boyle et al 1993). Some others argue the opposite, presenting 
alterations of p53 among early steps of neoplastic transformation. Furthermore, gene p53 
mutation has been hypothesized to be the earliest event in the development of a genetically 
altered field in oral mucosa, identifying an area of clonally related cells with malignant 
potential (Braakhuis et al 2003).  
Although LOH frequently appears in head and neck carcinogenesis at chromosome 3p, the 
genes at this region have not been well defined (Ha&Califano 2002). The fragile histidine 
triad (FHIT) gene has been identified on chromosome 3p14 as one candidate for TSG, 
altered by deletions in human tumours. The expression of FHIT protein has recently been 
studied in HNSCC and premalignant lesions (Yuge et al 2005). Loss of FHIT protein was 
observed in 42% of SCCs and 23% of premalignant lesions. There was no significant 
difference among the three grades of dysplasia and FHIT expression. The results of this 
study indicate that FHIT alterations may play an important role in early events of 
carcinogenesis.  
11. Key oncogenes in malignant alteration of SILs 
Chromosome region 11q13 has been identified as the site of several putative oncogenes, 
such as Bcl-1, int-2, hst-1, EMS-1 and cyclin D1⁄PRAD1 (Kim&Califano 2004). Amplification 
of 11q13 is detected in approximately one-third of HNSCCs, but only cyclin D1 has shown 
consistent overexpression⁄amplification (Jares et al 1994, Callender et al 1994). The function 
of proto-oncogene cyclin D1 is to activate Rb via phosphorylation, thus facilitating 
progression from the G1 phase to the S phase (Kim&Califano 2004). 
12. HPV-linked OSCC and OIN 
Besides the evident epidemiological meaning, HPV infection linked to OSCC development 
shows clinical implications as these patients have about half the risk of death with respect to 
HPV-negative OSCC ones (Fakhry et al 2006). Moreover, the incidence of the subsets of 
OSCC more frequently found associated with HPV infection, i.e. tongue and tonsillar 
cancers, has been rising in youngs with men and women 18 to 44 years old (67% of increase) 
for the past three decades, and the trend is actually most evident for young white women 
(Patel et al, 2011), whereas the OSCC incidence is declining for nonwhite men, for all age 
groups. These findings have been justified with the decrease of alcohol and smoke abuse, 
and the relative prevalence of infection with high-risk HPV strains, particularly in youngs. 
This identifies then distinct risk factor profiles for HPV-positive and HPV-negative OIN 
patients, and justifies the designation of clinical trials to assess the optimal treatment for 
these groups. From a histopathological point-of-view, the HPV-linked OIN are mostly 
undifferentiated (Carpenter et al 2011). 
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This is particularly intriguing, considerating that traditionally undifferentiated cancers have 
a very worse clinical outcome, being radio- and chemo-resistant, whereas HPV-linked 
undifferentiated OIN seems to have a better overall prognosis and a good response to post-
surgical therapy. 
For this reason, it seems fundamental to easily detect this subgroup of cancers and 
precancerous lesions, to preserve patients from overtreatment of their lesions. 
Since high-risk HPVs lead to the intracellular accumulation of p16INK4a protein, due to the 
E7 block of pRb, it has been proposed to utilize the immunohistochemical evaluation of p16 
for the screening of lesional tissue obtained from diagnostic biopsies. This has been shown 
to reliably predict the high-risk HPV infection in oral biopsies (Hoffmann et al 2010). 
The screening with IHC for p16 INK4a protein, then, may be regarded as a precious tool for 
the proper evaluation of the outcome and responsiveness to therapy of oral cancer and 
precancerous lesions. 
13. Key protein-based alterations in oral carcinogenesis 
Protein overexpression can appear as a consequence of gene amplification, increased DNA 
transcription and translation. Several gene products can influence cancer progression in this 
manner (Ha&Califano 2002 ). 
Epidermal growth factor receptor (EGFR), located on chromosome 7p12, codes for 
transmembrane growth-regulating receptor glycoprotein, which influences cell division, 
migration, adhesion, differentiation and apoptosis through a tyrosine kinase pathway 
(Pomerantz&Grandis 2004). The EGFR gene was found to be amplified in 25%, and its 
mRNA was overexpressed in 43% of oral SCCs. Half of the expressed cases occurred in the 
absence of detectable gene amplification. Both alterations appeared in advanced HNSCC 
(Irish&Bernstein 1993). Furthermore, overexpression of EGFR protein is an early event in 
carcinogenesis, rising with increasing degree of epithelial abnormalities, mainly in the 
progression of oral intraepithelial lesions to SCC (Shin et al 1994; Gale et al 1997). 
Eucaryotic initiation factor 4E (eIF4E) is a 24-kDa protein, which binds to mRNA as the 
initial rate-limiting step in protein synthesis. Amplification and overexpression of the eIF4E 
gene, located at chromosome 4q21, has been associated with malignant transformation in 
breast cancer and HNSCC. The proto-oncogene eIF4E was found to be elevated in 100% of 
HNSCCs and is of prognostic value in predicting recurrence (Sorrells et al 1999).  
14. Field cancerization 
In early 1953, Slaughter et al. proposed the clinical concept of field cancerization to explain 
the development of multiple cancers and precursor lesions in the head and neck area, 
particularly in the oral cavity. Their concept is based on long-term carcinogenic exposure, 
which causes the independent transformation of multiple epithelial cells at separate sites. 
Polyclonal tumours may independently arise from these spots. The so called histologically-
based field cancerization model has been gradually succeeded by a new one established on 
the basis of molecular changes of the affected mucosa. This hypothesis advocates a 
micrometastatic spread or a monoclonal theory, suggesting that a precancerous field of 
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mucosa may derive from an early genetic event that has undergone clonal expansion and 
lateral migration or expansion (Ha&Califano 2002, Califano et al 1996; 2000; Bedi et al 1996). 
Subsequent genetic alterations produce genetic divergence and various phenotypic 
alterations, resulting in a variety of histopathologically diverse regions in the local 
anatomical area and in the selection of various subclones. The theory, therefore, proposes a 
clonal origin of premalignant cells with successive lateral migration, and possible multiple 
primary tumours would not be monoclonal, but clonally related (Almadori et al 2004). 
15. Telomerase reactivation in malignant alteration of OIN 
The telomerase enzyme is a specialized multisubunit complex, with telomerase catalytic 
subunit (hTERT) functioning as a reverse transcriptase that can synthesize the telomeric 
ends at each cell division. Telomerase has been found to be re-activated in 90% of malignant 
neoplasms, including oral SCC (Meyerson et al 1996; Shay &Wright 1996, Luzar et al 2001). 
Recent studies have confirmed a close relationship between hTERT mRNA expression and 
telomerase activity, suggesting that quantification of hTERT gene expression can be used as 
an alternative to measurement of telomerase activity (De Kok et al 2000). These results 
suggest that telomerase re-activation is an early event in oral carcinogenesis, already 
detectable at the stage of precancerous oral epithelial changes.  
16. Additional markers of malignant alterations of oral intraepithelial 
neoplasia 
Several studies of OIN generally agree that the severity of epithelial abnormality reflects the 
degree of risk of SCC development (Jeannon et al 2004). No marker or group of markers has 
so far been identified as a reliable predictor of malignant progression of SILs. It is therefore 
under-standable that numerous studies have been devoted to the progression of OIN to 
invasive SCC. The role of cell-cycle proteins such as p16, p21, p27, p53, cyclin D1 and E have 
been extensively studied over the last two decades (Shin et al 1994; Fraczek et al 2007; 
Gorgoulis et al 1994; Gale et al 1997; Dolcetti et al 1992; Barbatis et al 1995; Nadal et al 1995; 
Poljak et al 1996; Uhlman et al 1996; Hirai et al 2003; Ioachim et al 2004; Wayne&Robinson 
2006). However, none of these markers has been found to have reliable predictive value. In 
addition, detection of proliferative activity, mainly as immunohistochemical labelling for 
pCNA and Ki67 antigens, can be used only as adjuncts to light microscopy for more 
objective and reliable histological grading of OIN (Leopardi et al 2001; Peschos et al 2005). 
Recent study of the transforming growth factor-beta (TGF-bRII) has indicated that its down-
regulation is an early event in oral carcinogenesis, which may occur in the loss of TGF- b-
mediated inhibition, thereby facilitating progression of precancerous lesions to SCC (Franchi 
A, 2001). Promising biomarkers for improving cancer detection include minichromosome 
maintenance proteins (Mcm-2-7), which assemble in the prereplication complex and are 
essential for DNA replication in eucaryotic cells. All six proteins are abundant throughout 
the cell cycle, being broken down rapidly on differentiation and more slowly in quiescence. 
In 2003 Chatrath et al found that Mcm-2 is expressed within the most superficial surface 
layer in cases of oral CIS and SCC and with minimal expression in basal-parabasal 
(abnormal) and atypical hyperplasia. The authors suggest that Mcm-2 would be a good 
biomarker for distinguishing premalignant from malignant lesions. Quantification of 
cellular DNA by image or flow cytometry has achieved acceptance as an objective and 
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reproducible component in diagnostic pathology. Several studies of oral intraepithelial 
lesions have shown that a proportion of these lesions show abnormal DNA content and that 
the incidence of this finding correlates with the degree of oral intraepithelial leions (Bracˇko 
1997; Munck-Wikland et al 1991; Crissman&Zarbo 1991). Bracˇko has additionally noted that 
lack of abnormal DNA does not exclude malignant alteration, since malignant tumours 
exhibit minimal chromosomal abnormalities resulting in DNA changes, which are below the 
threshold of sensitivity of measurement with the use of image analysis or flow cytometry. In 
2004, Kim and co-workers performed a study of quantitative PCR for genes specific to 
mitochondrial abundance in a spectrum of dysplastic head and neck lesions (Kim et al 
2004b). Their study shows that mitochondrial DNA is directly proportional to histo- 
pathological grade.  
17. Next-generation sequencing reveals NOTCH1 as an important tumor 
suppressor gene in head and neck cancer 
Recently (Brakenhoff 2011; License Number 2756960749906), two papers came out on 
Science (Agrawal 2011; Stransky 2011). Their aim has been to provide new insight into the 
genetic changes of Head&Neck-SCC that may suggest the development of alternative 
treatment strategies. By using a high-throughput technique called massively parallel 
sequencing or next-generation sequencing to analyze the genomes of head and neck cancers 
in great detail. Both groups sequenced the exons of all known human genes in tumor DNA 
and compared the sequence to that of the corresponding normal DNA of the same patient. 
In total, the genomic landscapes of 32 (Agrawal 2011) and 74 (Stransky 2011) tumors were 
examined, including tumors that were positive or negative for the human papillomavirus. 
Agrawal et al. also provided genetic profiling data on chromosomal changes, verified the 
mutations by classical Sanger sequencing, and validated some mutations in an additional 
panel of tumor and normal tissues. Mutations were found in many of the genes already 
known to play a role in HNSCC, such as TP53, CDKN2A, PIK3CA, PTEN, and HRAS, but at 
least one new cancer gene previously not known to be involved in HNSCC, NOTCH1, was 
identified. In both studies, inactivating mutations of NOTCH1 were found in 10 to 15% of 
the head and neck tumors, and it was the second most frequently mutated gene after TP53 
(which is mutated in 50 to 80% of the tumors). In several tumors, both alleles harbored 
mutations in NOTCH1. 
Why was NOTCH1 not found before in this type of cancer or even in other malignancies 
(Klinakis et al 2011,) as an important tumor suppressor? Functional studies had identified a 
role for NOTCH1 in squamous cell carcinogenesis, at least in the skin (Dotto 2008), but 
robust mutational data in clinical samples were missing. NOTCH1 is a very large gene 
consisting of 34 coding exons, which hampers classical (Sanger) DNA sequencing, thus 
demonstrating the major improvement afforded by next- generation sequencing platforms. 
The finding of numerous inactivating mutations in NOTCH1 in HNSCCs and the observation 
that mice with a disrupted NOTCH1 gene in the skin show a skin cancer phenotype (Nicolas 
et al 2003; Proweller et al 2006) provide strong evidence that NOTCH1 is an important tumor 
suppressor gene in HNSCC. NOTCH1 encodes a transmembrane receptor that functions in 
cell-to-cell communication (Ranganathan et al 2011) and is in the skin typically located in the 
cilia of the squamous cells, the dermal keratinocytes (Okuyama et al 2008; Ezratty et al 2011). 
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After ligand binding, the cytoplasmic tail of NOTCH is cleaved by a secretase enzyme, 
translocates to the nucleus, and functions as a transcription factor, driving the expression of 
numerous genes. All four NOTCH receptors encoded in the human genome are important for 
cell differentiation. Stransky et al. also found mutations in other cell differentiation-related 
genes, such as NOTCH2, NOTCH3, and TP63, suggesting that deregulation of the terminal 
differentiation program of mucosal keratinocytes is critical for squamous cancer development. 
This is not unexpected because terminal differentiation of normal keratinocytes in skin and 
mucosal epithelia is characterized by loss of cell organelles and even the nucleus during 
cornification—events that support the barrier function of squamous epithelia but which would 
inhibit malignant transformation. 
However, some questions remain. A high-throughput sequencing approach can reveal 
many mutations in a large number of genes, but this does not necessarily imply that these 
are all “driver mutations” causally related to the malignant transformation process. Tumors 
are genetically unstable and acquire many mutations including so-called “passenger 
mutations” (Sjoblom et al 2006; Wood et al 2007) that are a result of malignant 
transformation and not the cause. Functional studies in animal models are required to 
elucidate the exact role of the NOTCH receptors and the other genes that are mutated in 
HNSCC. As an example, Agrawal et al. indicated that they also found mutations in FBXW7 
in tumors that lack inactivating NOTCH1 mutations. The FBXW7 protein is a component of 
a ubiquitin ligase complex that targets NOTCH receptors for degradation by the 
proteasome, the protein degradation system of the cell, and this could be considered an 
inhibitory regulatory system of NOTCH1. Surprisingly, these FBXW7 mutations were also 
inactivating. One would have expected activating mutations in this inhibitory down- stream 
pathway, assuming that NOTCH1 is the target. Hence, this requires more detailed 
investigation. Relating mutations to phenotypic consequences is a challenge for all potential 
cancer genes identified by these high-throughput methods. Even non-synonymous 
mutations in established cancer genes may not always be driving, unless supported by 
functional testing in relevant models. 
An issue even more relevant to clinical application is that identification of a cancer gene does 
not mean that it is druggable. As Agrawal et al. note, proteins encoded by oncogenes (genes 
that, when activated, cause a normal cell to become cancerous) are most suited for treatments 
because inhibitory drugs will result in a reduction of cellular proliferation. However, in the 
case of inactivated or lost tumor suppressor proteins, inhibitors are of no use, and reactivation 
is complex or impossible. Instead, one has to make use of the principal of synthetic lethality—
finding another pathway that compensates the effect of, for example, NOTCH pathway 
inactivation (Iglehart&Silver 2009). Cancer-associated signaling pathways are often so critical 
for cellular homeostasis that there are mechanisms of redundancy to compensate inactivation, 
and these take over in tumor cells. Blocking this compensating pathway is then lethal for 
tumor cells, whereas in normal cells this has less effect as both pathways are active. This 
principle of synthetic lethality is a highly successful strategy, as shown by the application of 
poly(ADP-ribose) polymerase inhibitors in BRCA1- and BRCA2-deficient breast cancers (Fong 
et al 2009). However, the presence of such compensating pathways and their synthetic lethal 
character need to be identified. Hence, there is more work to be done, but the studies by 
Agrawal et al and Stransky et alindicate that there are more candidate cancer genes to be 
identified and we should keep searching for them. 
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18. Cancer stem cells in oral cancer 
The cancer stem cell hypothesis suggests that neoplastic clones are maintained exclusively 
by a rare fraction of cells with stem cell properties. Stem cells are defined as cells which are 
able to both extensively self-renew and differentiate into progenitors. Furthermore, stem 
cells are also attractive candidates as origin of cancers, as in their long lifespan they can 
acquire mutations and epigenetic changes that could favour the evolution toward 
malignancy. We discuss the evidences reported in literature on existence of cancer stem cells 
in oral cancer and mechanisms of the extrinsic and intrinsic circuitry controlling stem cell 
fate as well as their possible connections to cancer.  
Oral cancer is a culmination of continued hyperplasia or uncontrolled proliferation of basal 
epithelial stem cells. In a well differentiated tumor tissue, the suprabasal cells exhibits basal 
stem-like phenotype and differ from the terminal highly keratinized cells. Many 
experiments have compared the expression patterns of epidermal and oral epithelial stem 
cells (Kaur&Li 2000; Evander et al 1997). Up to now, no true stem cell population could be 
identified from both normal and tumor tissue of oral epithelium purely based on sorting for 
stem cell specific surface markers reported from epidermal tissue (Prince&Ailles 2008). The 
stratified squamous epithelia of the oesophagus and epidermis have different functions and 
embryological origins. The pursuit for specific oral epithelial stem cell surface markers lead 
to the identification of CD markers such as CD44 (Prince et al 2007; Naor et al 2008), CD147 
(Kose et al 2007; Toole et al 2008), integrins (Evander et al 1997), cytokeratins (Lindberg et al 
1989, Presland et al 2002), EpCAM/ESA (Trzpis et al 2007; Munz et al 2004), E-cadherin 
(Kudo et al 2004), along with transcription factors Oct-4, Nanog (Chiou et al 2008) and Bmi-1 
(Prince et al 2007). p75NGFR, a potential oral keratinocyte stem cell marker also co-localizes 
with BrdU incorporated stem cells and functions to mediate intercellular signaling in cell 
survival and apoptosis (Hatakeyama et al 2007; Nakamura et al 2007). An ideal cancer stem 
cell marker should impart all the acquired hallmarks of self-sufficiency in growth signals, 
anchorage-independent growth, apoptotic/drug resistance, invasiveness, metastatic 
potential in addition to primacy of high self- renewal conferred by cell of its origin, the 
normal stem cell. We discuss below several such stem cell markers representing the putative 
CSCs in oral squamous cell carcinoma and functional attributes bestowed by the expression 
pattern. 
Methods for the identification of CSCs in solid malignancies mirror those strategies 
employed to differentiate normal stem cells from their differentiated progeny. These include 
the efflux of vital dyes by multidrug transporters, the enzymatic activity of aldehyde 
dehydrogenase, colony and sphere-forming assays utilizing specific culture conditions and 
the most widely used method—the expression of specific cell surface antigens known to 
enrich for stem cells. Once the subpopulation of tumor cells has been identified and isolated, 
functional characterization through quantitative xenotransplantation assays, the gold-
standard for identification of CSCs, are used to assess the tumorigenicity and self- renewing 
potential of the putative CSC population in vivo  
18.1 Surface antigens 
By far the most common method of identifying CSCs has relied on the expression of specific 
cell-surface antigens that enrich for cells with CSC properties. Many of these antigens were 
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initially targeted because of their known expression on endogenous stem cells. While a 
multitude of studies have identified CSC markers across a variety of solid malignancies, 
relatively few of these markers have been studied in HNSCC. CD133. A pentaspan 
transmembrane glycoprotein localized on cell membrane protrusions (Costea et al 2006; 
Prince&Alley 2008), is a putative CSC marker for a number of epithelial malignancies 
including brain, prostate, colorectal, and lung (Chiou et al 2008; Kelly et al 2007). In HNSCC 
cell lines, CD133hi cells display increased clonogenicity, tumor sphere formation and 
tumorigenicity in xenograft models when compared to their CD133 low counterparts 
(Ramalho-Santos&Willenbring 2007; Singh et al 2004; Ricci-Vitiani et al 2007). CD44. A large 
cell surface glycoprotein involved in cell adhesion and migration. It is a known receptor for 
hyaluronic acid and interacts with other ligands such as matrix metalloproteases 
(Tan&Coussens 2007; Mimeault M, 2007). Initially identified as a solid malignancy CSC 
marker in breast cancer (Tabor et al 2002), Prince et al. demonstrated that CD44 expression 
could also be used to isolate a tumor subpopulation with increased tumorigenicity in 
HNSCC (Pillai&Nair 2000). Although CD44 expression enriches for cells with CSC 
properties, the relatively high number of cells required for tumor formation as compared 
with known CSC populations from other epithelial malignancies raises questions about 
whether CD44 expression alone is sufficient for isolation of a pure CSC population. Using 
primary human tumor samples as well as utilizing a more natural host microenvironment 
through an orthotopic xenograft model (Phesse&Clarke 2009) might reduce the number of 
cells needed to generate tumors.  
18.2 Aldehyde dehydrogenase activity  
Aldehyde dehydrogenase (ALDH) is an intracellular enzyme normally present in the liver. 
Its known functions include the conversion of retinol to retinoic acids and the oxidation of 
toxic aldehyde metabolites, like those formed during alcohol metabolism and with certain 
chemotherapeutics such as cyclophosphamide and cisplatin (Bosron et al 1988; Thomasson 
et al 1991; Visus et al 2007). ALDH activity is known to enrich hematopoetic 
stem/progenitor cells (Chute et al 2006) and more recently has been shown to enrich cells 
with increased stem-like properties in solid malignancies (Carpentino et al 2009; Croker et al 
2009, Deng et al 2010; Ma et al 2008). Chen et al. showed that ALDH activity correlated with 
disease staging in HNSCC and that higher enzymatic activity correlated with expression of 
epithelial-to-mesenchymal transition (EMT) genes as well as enriching cells with CSC 
properties (Chen et al 2009). Side Population. Hoechst 33342 is a fluorescent DNA- binding 
dye that preferentially binds to A-T rich regions. It is actively pumped out of cells by 
members of the ATP-binding cassette (ABC) transporter superfamily. Once stained with 
Hoechst dye, cells can be sorted by fluorescent-activated cell sorting (FACS) based upon the 
activity level of these multidrug transporters. Originally noted to enrich bone marrow for 
long-term hematopoetic stem cells (Clay et al 2010), this method has also been used to 
identify cells within solid tumors with increased tumorigenicity (Ho et al 2007; Szotek et al 
2006; Wang et al 2007). Side population (SP) cells from oral squamous cell carcinoma have 
been shown to have increased clonogenicity and tumorigenicity in xenotransplantation 
assays (Loebinger et al 2008). Furthermore, HNSCC SP cells displayed higher expression of 
known stem cell related genes—Oct4, CK19, BMI-1 and CD44—and lower expression of 
involucrin and CK13, genes associated with a differentiated status (Zhang et al 2009). 
www.intechopen.com
 Novel Markers for Diagnosis and Prognosis of Oral Intraepithelial Neoplasia 
 
19 
18.3 Tumor sphere formation 
Under serum-free culture conditions CSCs can be maintained in an undifferentiated state, 
and when driven toward proliferation by the addition of growth factors, form clonally 
derived aggregates of cells termed tumor spheres (Singh et al 2003). The ability of CSCs—
but not the remaining tumor bulk—to form tumor spheres has been used extensively in 
neural tumors to identify populations enriched for CSCs. In HNSCC, these spheres have 
been shown to be enriched for stem markers, including CD44hi (Okamoto et al 2009), Oct-4, 
Nanog, Nestin, and CD133hi (Zhang et al 2009), as well as exhibiting increased 
tumorigenicity in orthotopic xenografts (Chiou et al 2008). 
19. Cancer stem cells and disease progression 
While there exists significant data defining the presence of CSCs within a variety of tumor 
types and many aspects of the cell and molecular biology of CSC have been elucidated, the 
manner in which this unique cell population influences clinical disease progression remains 
unclear. Given that metastases can be formed from implantation of a single tumor cell 
(Fidler&Talmadge 1986), it seems likely that CSCs, as the progenitor of all tumor cell types, 
would be responsible for metastatic spread. Central to the CSC hypothesis is the presence of 
a unique stem cell “niche” or environment necessary to support the growth of stem cells 
(Li&Xie 2005). It has been shown that a premetastatic niche is established by the attraction of 
bone marrow derived cells to the future site of metastases by the secretion of factors from 
cancer cells and that blocking the creation of this premetastatic niche prevents metastases 
(Kaplan et al 2005). What these secreted factors are and whether they are secreted by CSCs 
or one of their progeny remains an open question; however, creation of this niche, possibly 
for the arrival of CSCs to form a metastasis, appears to be a crucial step in metastatic spread. 
Another stem cell marker, CD44, has also been implicated in metastatic spread and disease 
progression in HNSCC (Celetti et al 2005), although the CD44 story is more complex. 
Recently, three different isoforms, CD44 v3, v6, and v10, have been shown to be associated 
with progression and metastasis of HNSCC (Wang et al 2009). Increased CD44 v3 
expression in primary tumors was associated with lymph node metastasis, while CD44 v10 
expression was associated with distant metastasis and CD44 v6 expression was associated 
with perineural spread. In cell culture, blockade of these CD44 isoforms with isoform-
specific antibodies inhibited cellular proliferation, with the greatest inhibition seen with 
blockade of CD44 v6. Finally, increased expression of CD44 v6 and v10 was associated with 
shortened disease-free survival (Staibano et al 2007). These studies suggest that alteration in 
CSC phenotype through variation in CD44 isoform expression may alter the interaction of 
CSCs with the surrounding microenvironment. This may allow CSCs to more readily invade 
surrounding tissues or metastasize, thereby promoting disease progression. 
20. Treatment and evolution to malignancy 
To date, many researchers have reported that the risk of developing cancer from oral 
leukoplakia could not be significantly reduced by surgical intervention (Holmstrup et al 
2006; Vedtofte et al 1987; Schoelch et al 1999). Moreover, some review papers have stated 
that it is actually unclear whether removal of the lesion decreases malignant transformation 
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of oral leukoplakia because there is a lack of randomized controlled trials comparing the 
different treatment modalities (Lodi et al 2006, Lodi&Porter 2008). 
Nevertheless, the research by Amagasa et al. (2006; 2011a; 2011b) showed that the malignant 
transformation rate of leukoplakia treated by surgery was significantly lower than that 
without any treatment or that without surgery, so we believe that surgical excision with an 
adequate safety margin, coupled with well-timed evaluation of oral leukoplakia on follow-
up, is effective in preventing the malignant transformation of these lesions.  
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